2 results
Approved WMOCompleted
Primary• To evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-…
Approved WMOCompleted
The SyncAV Post-Market Trial will evaluate changes in LV end-systolic volume (LVESV) between baseline (before CRT implant) and 12 months (post-randomization) in patients with CRT devices programmed with SyncAV compared to patients with CRT devices…